Low PR in ER(+)/HER2(−) breast cancer: High rates of TP53 mutation and high SUV

Sung Gwe Ahn, Chang Ik Yoon, Jae Hoon Lee, Hye Sun Lee, So Eun Park, Yoon Jin Cha, Chihwan Cha, Soong June Bae, Kyung A. Lee, Joon Jeong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

On the basis of TP53 mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational analysis of exons 5-9 of the TP53 gene was conducted using PCR amplification and direct sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight (10.3%) tumors had a somatic TP53 mutation. The TP53 mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%, P = 0.039). Low-PR tumors had significantly higher median SUVs than high-PR tumors (P = 0.046). The multivariable analysis revealed that SUV and age remained independent variables associated with low PR expression. An adverse impact of low PR expression on recurrence-free survival was observed in the multivariable Cox regression hazard model. We provide clinical evidence that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.

Original languageEnglish
Pages (from-to)177-185
Number of pages9
JournalEndocrine-Related Cancer
Volume26
Issue number2
DOIs
Publication statusPublished - 2019 Feb

Fingerprint

Mutation Rate
Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
p53 Genes
Fluorodeoxyglucose F18
Neoplasms
Positron-Emission Tomography
Mutation
human ERBB2 protein
Proportional Hazards Models
Exons
Glucose
Recurrence
Polymerase Chain Reaction
Survival

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Ahn, Sung Gwe ; Yoon, Chang Ik ; Lee, Jae Hoon ; Lee, Hye Sun ; Park, So Eun ; Cha, Yoon Jin ; Cha, Chihwan ; Bae, Soong June ; Lee, Kyung A. ; Jeong, Joon. / Low PR in ER(+)/HER2(−) breast cancer : High rates of TP53 mutation and high SUV. In: Endocrine-Related Cancer. 2019 ; Vol. 26, No. 2. pp. 177-185.
@article{d6ae101dcebe4554a73eeba790726eb2,
title = "Low PR in ER(+)/HER2(−) breast cancer: High rates of TP53 mutation and high SUV",
abstract = "On the basis of TP53 mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational analysis of exons 5-9 of the TP53 gene was conducted using PCR amplification and direct sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight (10.3{\%}) tumors had a somatic TP53 mutation. The TP53 mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1{\%} vs 7.9{\%}, P = 0.039). Low-PR tumors had significantly higher median SUVs than high-PR tumors (P = 0.046). The multivariable analysis revealed that SUV and age remained independent variables associated with low PR expression. An adverse impact of low PR expression on recurrence-free survival was observed in the multivariable Cox regression hazard model. We provide clinical evidence that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.",
author = "Ahn, {Sung Gwe} and Yoon, {Chang Ik} and Lee, {Jae Hoon} and Lee, {Hye Sun} and Park, {So Eun} and Cha, {Yoon Jin} and Chihwan Cha and Bae, {Soong June} and Lee, {Kyung A.} and Joon Jeong",
year = "2019",
month = "2",
doi = "10.1530/ERC-18-0281",
language = "English",
volume = "26",
pages = "177--185",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "2",

}

Ahn, SG, Yoon, CI, Lee, JH, Lee, HS, Park, SE, Cha, YJ, Cha, C, Bae, SJ, Lee, KA & Jeong, J 2019, 'Low PR in ER(+)/HER2(−) breast cancer: High rates of TP53 mutation and high SUV', Endocrine-Related Cancer, vol. 26, no. 2, pp. 177-185. https://doi.org/10.1530/ERC-18-0281

Low PR in ER(+)/HER2(−) breast cancer : High rates of TP53 mutation and high SUV. / Ahn, Sung Gwe; Yoon, Chang Ik; Lee, Jae Hoon; Lee, Hye Sun; Park, So Eun; Cha, Yoon Jin; Cha, Chihwan; Bae, Soong June; Lee, Kyung A.; Jeong, Joon.

In: Endocrine-Related Cancer, Vol. 26, No. 2, 02.2019, p. 177-185.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low PR in ER(+)/HER2(−) breast cancer

T2 - High rates of TP53 mutation and high SUV

AU - Ahn, Sung Gwe

AU - Yoon, Chang Ik

AU - Lee, Jae Hoon

AU - Lee, Hye Sun

AU - Park, So Eun

AU - Cha, Yoon Jin

AU - Cha, Chihwan

AU - Bae, Soong June

AU - Lee, Kyung A.

AU - Jeong, Joon

PY - 2019/2

Y1 - 2019/2

N2 - On the basis of TP53 mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational analysis of exons 5-9 of the TP53 gene was conducted using PCR amplification and direct sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight (10.3%) tumors had a somatic TP53 mutation. The TP53 mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%, P = 0.039). Low-PR tumors had significantly higher median SUVs than high-PR tumors (P = 0.046). The multivariable analysis revealed that SUV and age remained independent variables associated with low PR expression. An adverse impact of low PR expression on recurrence-free survival was observed in the multivariable Cox regression hazard model. We provide clinical evidence that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.

AB - On the basis of TP53 mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone TP53 gene sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational analysis of exons 5-9 of the TP53 gene was conducted using PCR amplification and direct sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight (10.3%) tumors had a somatic TP53 mutation. The TP53 mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%, P = 0.039). Low-PR tumors had significantly higher median SUVs than high-PR tumors (P = 0.046). The multivariable analysis revealed that SUV and age remained independent variables associated with low PR expression. An adverse impact of low PR expression on recurrence-free survival was observed in the multivariable Cox regression hazard model. We provide clinical evidence that genetic alteration of the TP53 gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85059892972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059892972&partnerID=8YFLogxK

U2 - 10.1530/ERC-18-0281

DO - 10.1530/ERC-18-0281

M3 - Article

AN - SCOPUS:85059892972

VL - 26

SP - 177

EP - 185

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -